2 chapters across the catalog
An interim FTC report alleges that PBMs aggressively steer patients toward high-cost specialty drugs and preferred pharmacies to maximize profits. For example, a generic leukemia drug costing $66 was reimbursed at $2,700. Former FDA Commissioner Scott Gottlieb explains how the "back-ended rebate" system allows PBMs and insurers to profit while patients pay high out-of-pocket costs at the pharmacy counter.
Pharmacy Benefit Managers and the "Middleman" Drug Scam
The role of Pharmacy Benefit Managers (PBMs) is identified as a primary driver of high drug costs through "spread pricing" and rebate scams. These middlemen allegedly inflate the price of generic drugs and pocket the difference, which President Trump's new executive orders seek to eliminate by mandating that rebates go directly to consumers.
